The Non-Malignant Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | 3-year COMMODORE-1 data support long-term crovalimab in PNH
Yasutaka Ueda, MD, PhD, Osaka University, Suita, Japan, discusses 3-year data from the COMMODORE-1 study (NCT04432584) evaluating crovalimab in patients with paroxysmal nocturnal hemoglobinuria (PNH) who switched from ravulizumab. He highlights sustained efficacy, a favorable long-term safety profile, and the potential of subcutaneous crovalimab as a convenient long-term treatment option. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So PNS treatment has been dramatically changed after C5 inhibitors were introduced. And now many patients are on C5 inhibitors. Now here there is a new C5 inhibitor, clobimab. Clobimab is a recombinant antibody that is dosed subcutaneously every four weeks. So the primary target of this study is to examine the safety and efficacy of clobimab in a long-term treatment period of three years. So in this cohort, only a small number of patients, 38 patients, were enrolled in this RM analysis of the COMMODORE-1, which included the patients who were treated with labrisizumab and fistulizumab...
So PNS treatment has been dramatically changed after C5 inhibitors were introduced. And now many patients are on C5 inhibitors. Now here there is a new C5 inhibitor, clobimab. Clobimab is a recombinant antibody that is dosed subcutaneously every four weeks. So the primary target of this study is to examine the safety and efficacy of clobimab in a long-term treatment period of three years. So in this cohort, only a small number of patients, 38 patients, were enrolled in this RM analysis of the COMMODORE-1, which included the patients who were treated with labrisizumab and fistulizumab. So the conclusion of this poster is that clobimab is safe, well-tolerated, and shows the same efficacy as other clinical trials of clobimab. So, the most important point is that the efficacy has been maintained through three years without any new sign of safety signal.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
